Healthcare / Medical Instruments & SuppliesJakarta
$800.00
+5.00 (+0.63%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $225.9B · quality 79.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.04T
P/E
10.2x
↓EV/EBITDA
8.0x
↓ROE
31.6%
↑Gross Margin
50.4%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.5%
FCF CAGR
+11.8%
FCF margin
27.0%
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $837.31B · net income $283.88B · FCF $225.89B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $837.31B | $837.31B | $909.99B | $559.47B | $823.66B |
| Net Income | $283.88B | $283.88B | $286.54B | $156.02B | $243.09B |
| EBITDA | $376.22B | $376.22B | $379.79B | $213.92B | $329.71B |
| EPS | 74.70 | 74.70 | 75.40 | 41.06 | 63.97 |
| Gross Margin | 50.4% | 50.4% | 48.5% | 47.1% | 48.9% |
| Operating Margin | 41.8% | 41.8% | 38.9% | 34.3% | 39.5% |
| Net Margin | 33.9% | 33.9% | 31.5% | 27.9% | 29.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.04 | 0.07 | 0.14 |
| Current Ratio | 6.73 | 6.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $225.89B | $225.89B | $331.29B | $217.52B | $161.64B |
| Returns | |||||
| ROE | 31.6% | 31.6% | 33.4% | 18.6% | 28.9% |
| Valuation | |||||
| P/E | 10.23 | 10.23 | 14.32 | 15.59 | 9.77 |
| EV/EBITDA | 8.02 | 8.02 | 10.69 | 11.38 | 7.42 |
| P/B | 3.38 | 3.38 | 4.78 | 2.90 | 2.82 |
| Growth & Yield | |||||
| Revenue Growth | -8.0% | -8.0% | 62.7% | -32.1% | — |
| EPS Growth | -0.9% | -0.9% | 83.6% | -35.8% | — |
| Dividend Yield | 15.1% | 15.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-1.7%
EPS terminal req.
$70.99
Spread vs growth
0.8%
5Y implied EPS CAGR
2.8%
EPS terminal req.
$85.89
Spread vs growth
-3.8%
10Y implied EPS CAGR
6.4%
EPS terminal req.
$138.33
Spread vs growth
-7.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+12.7%
Start / end P/E
10.9x → 10.7x
EPS bridge
75.40 → 74.70
Residual
+0.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.